
-
Iran, US to hold second round of high-stakes nuclear talks in Rome
-
Humanoid robots stride into the future with world's first half-marathon
-
Migrant's expulsion puts Washington Salvadorans on edge
-
Plan for expanded Muslim community triggers hope, fear in Texas
-
Pakistan foreign minister due in Kabul as deportations rise
-
White House touts Covid-19 'lab leak' theory on revamped site
-
Dodgers star Ohtani skips trip to Texas to await birth of first child
-
SFWJ / Medcana Announces Strategic Expansion Into Australia With Acquisition of Cannabis Import and Distribution Licenses
-
US senator says El Salvador staged 'margarita' photo op
-
Ford 'adjusts' some exports to China due to tariffs
-
Thomas maintains two-shot lead at RBC Heritage
-
US to withdraw some 1,000 troops from Syria
-
Four killed after spring storms wreak havoc in the Alps
-
Spurs' Popovich reportedly home and well after 'medical incident'
-
Trump goes to war with the Fed
-
Celtics chase second straight NBA title in playoff field led by Thunder, Cavs
-
White House site blames China for Covid-19 'lab leak'
-
Norris edges Piastri as McLaren top Jeddah practice
-
Trump warns US could ditch Ukraine talks if no progress
-
Judge denies Sean 'Diddy' Combs push to delay trial
-
80 killed in deadliest US attack on Yemen, Huthis say
-
Lebanon says two killed in Israeli strikes in south
-
Trump says US will soon 'take a pass' if no Ukraine deal
-
F1 success is 'like cooking' - Ferrari head chef Vasseur
-
Cycling mulls slowing bikes to make road racing safer
-
Macron invites foreign researchers to 'choose France'
-
Klopp 'happy' in new job despite Real Madrid rumours: agent
-
Alcaraz into Barcelona semis as defending champion Ruud exits
-
Vance meets Italy's Meloni before Easter at the Vatican
-
Evenepoel returns with victory in Brabantse Pijl
-
Maresca confident he will survive Chelsea slump
-
Mob beats to death man from persecuted Pakistan minority
-
Lebanon says one killed in Israeli strike near Sidon
-
Arsenal's Havertz could return for Champions League final
-
US officials split on Ukraine truce prospects
-
Client brain-dead after Paris cryotherapy session goes wrong
-
Flick demands answers from La Liga for 'joke' schedule
-
'Maddest game' sums up Man Utd career for Maguire
-
Trial opens for students, journalists over Istanbul protests
-
Gaza rescuers say Israeli strikes kill 24 after Hamas rejects truce proposal
-
'Really stuck': Ukraine's EU accession drive stumbles
-
'Not the time to discuss future', says Alonso amid Real Madrid links
-
74 killed in deadliest US attack on Yemen, Huthis say
-
Southgate's ex-assistant Holland fired by Japan's Yokohama
-
Vance meets Meloni in Rome before Easter at the Vatican
-
Ryan Gosling to star in new 'Star Wars' film
-
Hamas calls for pressure to end Israel's aid block on Gaza
-
Russia says Ukraine energy truce over, US mulls peace talks exit
-
58 killed in deadliest US strike on Yemen, Huthis say
-
Museums rethink how the Holocaust should be shown

MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems.
The Reveal® G4 HIV-1/2 antibody rapid test (Reveal® G4 HIV) is the world's fastest HIV rapid test. Based on MedMira's patented Rapid Vertical Flow Technology, the Reveal® G4 HIV offers a simple testing solution with immediate results which do not fade away. Therefore, offering the best rapid testing solution which is FDA approved since 2004. The Reveal® G4 HIV is offered in three convenient formats (Point-of-Care finger-stick whole blood, Laboratory format Serum/Plasma and venipuncture whole blood) to accommodate any health care setting without the need for timing devices. With its unique built-in procedural and reagent control line, an operator can be assured that each test has been performed correctly.
A unique feature of MedMira's patented technology is the elimination of the prozone (hook) effect, a known common issue in traditional serological tests, where a high concentration of antibodies can lead to false-negative results. MedMira's technology avoids this by ensuring antibody binding occurs in a controlled, localized environment, while excess antibodies are washed away. The result is a highly accurate test that maintains reliability across a wide range of antibody levels.
As MedMira's SDVOSB Vendor, Lovell is excited to bring this product to federal healthcare providers. MedMira is now available through the Department of Veterans Affairs' Federal Supply Schedule (FSS), GSA Advantage, the Defense Logistics Agency's Electronic Catalog (ECAT), and the Department of Defense's Distribution and Pricing Agreement (DAPA). Listing products on contract vehicles with Lovell streamlines the acquisition process while helping government agencies meet their SDVOSB procurement goals.
"We're proud to partner with MedMira to bring an advanced rapid testing solution to federal healthcare providers. The speed and reliability of their Reveal® G4 platform supports clinicians in making timely decisions and improves the care experience for our veterans," said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.
"MedMira is proud to partner with Lovell Government Services, SDVOSB, to support Federal procurement needs through their eCAT, GSA, and VA FSS contract vehicles," said Nicole Crenshaw, VP of Commercial Operations at MedMira. "This strategic partnership provides us with the critical reach into key government markets, enabling greater access to our innovative diagnostic solutions where they're needed most."
About MedMira
MedMira is the developer and owner of Rapid Vertical Flow (RVF)® Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal®, Multiplo® and Miriad® brands in global markets. MedMira's HIV rapid test has been the first approved in Canada and the second HIV rapid test approved in the United States.
For more information visit medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For Media Inquiries:
Markus Meile
[email protected]
902-450-1588
About Lovell Government Services
Lovell Government Services has been a trusted SDVOSB vendor since 2013 with a proven track record of successfully introducing suppliers to the government market. Lovell is a three-time Inc. 5000 honoree and leader in the federal space. They partner with medical and pharmaceutical companies looking to better serve Veteran and military patient populations, increase their federal revenue stream, and win government contracts.
Learn more at www.lovellgov.com
For Media Inquiries:
Jeff McKay
[email protected]
850-912-4680
SOURCE: MedMira, Inc.
View the original press release on ACCESS Newswire
L.Miller--AMWN